Sun Pharma Funds $2.5 Million Dermatology Chair at Mount Sinai

The grant, managed within the Kimberly and Eric J. Waldman Department of Dermatology, aims to institutionalize research, mentorship, and clinical training. By securing this perpetual funding, the school intends to bridge the gap between emerging laboratory findings and practical patient care. Sun Pharma, currently the second-largest dermatology-focused pharmaceutical company in the U.S. by prescription volume, views this investment as a strategic effort to foster innovation in inflammatory skin disease treatment.

Dr. Lebwohl, who serves as Dean for Clinical Therapeutics at Mount Sinai, is recognized internationally for his work in psoriasis research and his previous leadership as President of the American Academy of Dermatology. His appointment marks the commencement of the professorship’s mission to prepare future generations of dermatologists. According to Dr. Emma Guttman, the department’s system chair, the endowment serves as a critical mechanism to sustain the rapid progress seen in the field over recent decades.